ClinicalTrials.gov
ClinicalTrials.gov Menu

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03110107
Recruitment Status : Recruiting
First Posted : April 12, 2017
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Condition or disease Intervention/treatment Phase
Advanced Cancer Biological: Ipilimumab Biological: BMS-986218 Biological: Nivolumab Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 452 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors
Actual Study Start Date : April 28, 2017
Estimated Primary Completion Date : April 6, 2020
Estimated Study Completion Date : March 20, 2021

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Monotherapy
Ipilimumab Monotherapy and BMS-986218 Monotherapy
Biological: Ipilimumab
Specified dose on specified days
Other Name: Yervoy
Biological: BMS-986218
Specified dose on specified days
Experimental: Combination Therapy
BMS-986218 in combination with Nivolumab
Biological: BMS-986218
Specified dose on specified days
Biological: Nivolumab
Specified dose on specified days
Other Name: Opdivo



Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) [ Time Frame: Up to 4 years ]
    Safety and tolerability as measured by incidence of AEs

  2. Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 4 years ]
    Safety and tolerability as measured by incidence of SAEs

  3. Objective Response Rate (ORR) of BMS-986218 monotherapy relative to Ipilimumab in immuno-oncology (IO) progressed melanoma cohort [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab

  4. Median Duration of Response (mDOR) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab

  5. Progression Free Survival (PFS) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab


Secondary Outcome Measures :
  1. ORR of BMS-986218 alone or in combination with Nivolumab [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors

  2. mDOR of BMS-986218 alone or in combination with Nivolumab [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors

  3. PFS of BMS-986218 alone or in combination with Nivolumab [ Time Frame: Up to 4 years ]
    Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors

  4. Incidence of anti-drug antibody (ADA) to BMS-986218 [ Time Frame: Up to 4 years ]
    Summary measures of pharmacokinetics (PK) parameters and incidence of ADA to BMS-986218

  5. Percentage of change from baseline in T-regulatory cells (Tregs) [ Time Frame: Up to 4 years ]
    Summary measures of Tregs and correlation/measure of association of anti-tumor activity and change (or % change) from baseline in Tregs

  6. Maximum observed serum concentration (Cmax) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  7. Time of maximum observed concentration (Tmax) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  8. Area under the concentration-time curve from time zero to the time of the [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  9. Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  10. Trough observed serum concentration (Ctrough) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  11. Total body clearance (CLT) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  12. Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  13. Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)] [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  14. Terminal serum half-life if data permit (T-HALF) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters

  15. Observed concentration at the end of a dosing interval (Ctau) [ Time Frame: Up to 4 years ]
    Summary measures of PK parameters



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
  • histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable)
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Participants must have received, and then progressed, relapsed, or been intolerant to, all standard treatment regimens with proven survival benefit in the advanced or metastatic setting according to tumor type, if such a therapy exists

Exclusion Criteria:

  • Participants with primary CNS malignancies, or tumors with CNS metastases as the only site of disease, will be excluded
  • Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
  • Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or immunotherapy (including anti-PD-1/PD-L1) are permitted

Other protocol defined inclusion/exclusion criteria could apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03110107


Contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #

Locations
United States, Colorado
Local Institution Withdrawn
Aurora, Colorado, United States, 80045
United States, Nevada
Local Institution Withdrawn
Las Vegas, Nevada, United States, 89128
United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Martin Gutierrez, Site 0002    551-996-5900      
United States, New York
Columbia University Medical Center (Cumc) Recruiting
New York, New York, United States, 10032
Contact: Charles Drake, Site 0001    646-317-3141      
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Claire Friedman, Site 0007    281-208-6570      
United States, Pennsylvania
University Of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Mark O'Hara, Site 0004         
France
Local Institution Not yet recruiting
Lyon Cedex 08, France, 69373
Contact: Site 0019         
Local Institution Not yet recruiting
Toulouse Cedex 9, France, 31059
Contact: Site 0020         
Local Institution Not yet recruiting
Villejuif, France, 94805
Contact: Site 0018         
Israel
Local Institution Not yet recruiting
Ramat Gan, Israel, 52621
Contact: Site 0008         
Italy
Local Institution Not yet recruiting
Napoli, Italy, 80131
Contact: Site 0011         
Local Institution Not yet recruiting
Siena, Italy, 53100
Contact: Site 0010         
Spain
Local Institution Not yet recruiting
Barcelona, Spain, 08035
Contact: Site 0014         
Local Institution Not yet recruiting
Madrid, Spain, 28050
Contact: Site 0013         
Local Institution Not yet recruiting
Pamplona, Spain, 31008
Contact: Site 0012         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT03110107     History of Changes
Other Study ID Numbers: CA022-001
2017-000597-11 ( EudraCT Number )
First Posted: April 12, 2017    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Antibodies
Antibodies, Monoclonal
Nivolumab
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents